

Index

- Abus de droit*, 317
- Abuse of IP rights, 316, 330
 abuse of patents, 155, 288
 Article 5A(2) of the Paris Convention
 failure to work, 317
 strategic litigation or sham litigation, 318
- Abuse of rights, 316
- Access to essential goods, 281
- Access to ESTs, 82, 97, 110, 121, 148, 234, 254,
 304, 307, 313, 354, 359
- Access to know-how, 362
- Access to knowledge, 74, 140
- Access to medicine, 216, 220, 222, 234, 261, 277,
 298
- Access to patent information, 131
- Access to technology, 49, 63, 78, 132, 206, 285,
 321
- ACTA, 72
- Ad Hoc Working Group on Long-Term
 Co-operative Action, 104
- African Group, 220, 261
- Agenda 21, 14, 97, 195, 283
- ALBA Countries, 100
- Ambiguous obligations and exceptions, 210
- Andean Community, 252
- Anell Draft, 324
- Anglo-American legal tradition, 31
- Annex I countries, 90
- Annex II countries, 82, 91, 100
- Anti-competitive practices, 143–55, 230, 279,
 281, 293, 296, 301, 312–13, 328, 336, 338,
 339, 343, 345
 blockage, 145–48
 block market entry, 145
 strategic patenting, 145
 contractual restraints, 311
 exclusive grant back, 153
 export restrictions, 153, 335
 grant-back provisions, 335
 high licensing fees, 148–50
 limitation to follow-on innovation, 335
 limiting follow-on innovation, 153
 Mexico – Telecoms (2004), 333
 refusal to license, 150–53
 unilateral conduct, 311
- Anti-patent proposal, 241
- Appellate Body, 161, 164, 167, 171–72, 174, 255
- Article 2.1(g) of VCLT, 184
- Article 31 of VCLT, 84, 169–70, 192, 268, 297,
 303, 308, 344, 355, 360
 General Rule of Interpretation, 162
 the principle of good faith, 164
- Article 31(1) of VCLT
 context, 174–76
 object and purpose, 172–73
 ordinary meaning, 170–72
 the principle of good faith, 164–70
- Article 31(2) of VCLT
 context, 175
- Article 31(3)(a) of VCLT, 215
 subsequent agreement, 177–79
- Article 31(3)(b) of VCLT
 negotiating history, 181
 subsequent practice, 179–81
- Article 31(3)(c) of VCLT, 229
 principle of systemic integration, 182
 relevant rules of international law, 181–86
 *US – Anti-Dumping and Countervailing
 Duties* (2011), 183
- Article 32 of VCLT, 162–63
 supplementary means of interpretation, 174,
 186–92

- Articles 31 and 32 of VCLT, 231, 261, 313, 350
 Authoritative interpretation, 261, 328
- Balance
 between competing public policy interests, 257
 between creating incentives for innovation and ensuring access to new technologies, 60
 between intellectual property rights and other important socio-economic objectives, 207
 between IP protection and competition, 322
 between patent policy and the policy favouring free competition, 118
 between the private rights and the objective of public policy, 205
 between the protection of IPRs and access to technologies, 156
 between the protection of the exclusive rights and the social goals of the wider transfer of ESTs, 156
 between the public and private spheres, 24
 between traditional development-oriented international treaties and emerging environmental norms, 200
- Balance and weigh, 202
- Balanced and pro-competitive interpretation, 346
- Balanced and tailored interpretation of IP-related obligations, 214, 351
- Bali Climate Summit, 358
- Bangladesh, 307
- BASIC Group, 99
- Berne Convention, 66, 190
 Article 9.2, 260
- Blanket exclusions of ESTs, 309
- Bolar exemption, 262, 267
- Bona fide*, 287–88, 301, 308, 352
- Brazil, 33, 37, 137, 275, 305
 Brazil – Retreaded Tyres (2007), 210, 255
 Brazil's 1996 Industrial Property Law, 239
 Brazil's HIV/AIDS program, 239
 Brazil's 1996 Industrial Property Law
 Article 68(1), 285
- BRIC, 39, 41, 45
- Brundtland Report, 198
- Brussels Ministerial Text, 324
- Canada
 Canada – Pharmaceutical Patents (2000), 167, 176, 190, 207, 212, 227, 243, 245, 259, 262, 287
 Canada – Pharmaceutical Products (2000), 131
 Canada's Patent Act, 262
- Cancun
 Cancun Agreement, 94, 105
 Cancun meeting, 105
- CBD, 49, 79
 Article 16, 84
- CBDR, 79–82
 a political necessity, 81
 Article 3.1 of the UNFCCC, 80
 common responsibilities, 80
 differentiated responsibilities, 80
 historical contribution to problems, 81
 Principle 7 of the Rio Declaration, 79
- Chairman's Draft Text of 23 November 1990, 334
- Chapter 34 of Agenda 21, 12, 97
- Characteristics of technologies, 121
- Chatham House Report, 35, 137
- China, 12, 20, 33, 35–37, 97, 137, 152, 154
 China – Intellectual Property Rights (2009), 66
 China – Publications and Audiovisual Products (2009), 171
 China – Rare Earths (2014), 201
 China – Raw Materials (2012), 195
- Circumstances of the conclusion, 174, 189–90
- EC – *Chicken Cuts* (2005), 173
- CJEU, 274, 316, 340
 IMS (2004), 341
 Magill (1995), 340
 Microsoft (2007), 341
- Clean Development Mechanism, 90–91
- Clean energy technologies, 36, 38, 126–27, 153, 291
- Climate change, 234
 common concern of mankind, 1, 211
 major contributor to, 15
 national emergency or other circumstances of extreme urgency, 360
 resolution of 43/53 of 1988, 1
 the defining challenge of our era, 1
- Climate change adaptation technologies, 114
- Climate change mitigation, 15, 232, 290, 301, 350
- Climate change mitigation technologies, 38, 306
- Climate change negotiations, 148, 241, 256, 348–49
- Climate Technology Centre and Network, 94–95

- Combating climate change
 - immediate and urgent global priority, 302
- Commitments to transfer ESTs, 351
- Common concern of mankind, 1, 232, 235, 301, 351
- Common intentions of the parties, 189, 191, 214
- Commonwealth, 272
- Competing public values, 213
- Competition law, 283, 312–13, 321–22, 330, 332, 336
- Competition policy, 277, 312–13, 322
- Competition threats, 152
- Competition-related flexibilities, 313, 354–55
- Competition-related provisions, 5, 160, 313, 343, 354
- Competitive advantage, 23, 36, 125, 140, 144, 146–47, 153, 311, 325, 349
- Compulsory licences, 227, 259, 278–83, 287, 299, 351
 - adequate remuneration, 279
 - level of remuneration*, 294
 - taking into account*, 294
 - adequate remuneration (Article 31(h)), 293
 - appropriateness and effectiveness, 305
 - Article 31 of the TRIPS Agreement, 281
 - Article 31(k), 313–37
 - Article 5A(2) of the Paris Convention, 279
 - circumstances of extreme urgency, 224
 - conditions, 303
 - conditions and procedural requirements, 291–97
 - independent review*, 293
 - on its individual merits*, 291
 - prior negotiation requirement*, 292
 - environmental protection, 290
 - grounds, 282–83
 - lack of local working, 301
 - legitimate interest of the compulsory licensee, 295
 - level of compensation, 303
 - national emergency, 224
 - climate change*, 302
 - non-working of the invention, 286
 - on its individual merits, 303
 - on the grounds of mitigating climate change, 301
 - predominantly for domestic use, 306
 - predominantly for the supply of the domestic market, 296
 - protection of legitimate interest, 295
 - refusal to license, 343
 - scope and duration, 295
 - non-assignable*, 296
 - non-exclusive*, 296
 - several goals, 279
 - threat of, 300
 - threat thereof, 304
 - UK Patents Act, 284
- Compulsory licensing, 54, 99, 102, 303–4, 360
- Conference of the Parties, 84
 - COP-13, 91–93
 - COP-16, 94
 - COP-3, 87
 - COP-7, 90, 92
 - COP-8, 82
- Consent, 18, 73, 113, 116, 215, 257, 271, 278, 281
- Consistency requirement
 - Articles 31 and 40, 323
 - Articles 7 and 8.1, 323
 - Articles 8.2 and 40.2, 322–24
 - basic balance of rights and obligations, 211
 - divergent interpretations, 210
 - Preamble, 323
- Constructive ambiguity, 160
- Consumer protection, 277
- Consumer welfare, 341
- Contemporary concerns of the community of nations, 231
 - US – *Shrimp* (1998), 226
- Contemporary international concern, 223
- Context, 174–76
 - “may shed light” on the meaning, 174
 - agreement, 175
 - US – *Section 110 (5) Copyright Act* (2000), 175
 - annexes of treaties, 174
 - Article 31(1) of VCLT, 174
 - Article 31(2) of VCLT, 174
 - Canada – *Pharmaceutical Patents* (2000), 176
 - Korea – *Dairy Safeguards* (1999), 174
 - preamble, 174
 - related to the treaty, 175
 - EC – *Chicken Cuts* (2005), 175
 - US – *Section 110 (5) Copyright Act* (2000), 175
- Contextual elements, 214
 - Article 31(3) of the VCLT, 176
 - EC – *Approval and Marketing of Biotech Products* (2006), 230
 - obligatory character, 176
- Copenhagen, 4, 94, 98, 103
- Copenhagen Accord, 105
- Copenhagen Climate Summit, 98
- Copenhagen negotiations, 104

- Council for TRIPS, 45, 67–68, 76, 78, 297
- Court of First Instance of the EU
 - Microsoft v. Commission*, 332
- Covered agreements, 161, 167, 193
- Customary rules of interpretation of public international law, 192, 236, 372
 - Articles 31 and 32 of VCLT, 161
- Customs territories, 184
- Danish Text, 104
- De jure* discrimination, 112
- Decision
 - Decision of 30 August 2003, 224
 - Decision of the Ministerial Conference on Implementation-Related Issues and Concerns, 76
 - Decision on Trade and Environment, 195
- Declaration on Intellectual Property and Climate Change, 359
- Declaration on Patents Protection: Regulatory Sovereignty under TRIPS, 264
- Developed countries, 2, 18, 28, 38, 45, 49, 54, 60, 71, 75, 81, 86, 97, 101, 160
- Developing countries, 26, 42, 48–49, 51, 71–72, 79, 85–86, 89, 101
- Development & Employment Alliance, 101
- Development Agenda, 72
- Development and technological objectives, 205
- Differential pricing, 277
- Differential treatment, 288
 - ESTs, 308
 - fast track mechanisms, 246
- Disclosure requirement, 284
- Dispute settlement panels, 255, 286
- Doha Declaration, 179, 192, 206, 228, 236, 276, 281, 283, 289, 296, 298–99, 302, 308, 351, 358
 - access to medicines for all, 223
 - exhaustion regime, 224
 - implications, 224–26
 - Paragraph 4, 211, 216, 288
 - Paragraph 5(b), 287
 - Paragraph 6, 224, 297
 - insufficient or no manufacturing capacities*, 224
 - political obstacle, 225
 - precedent, 226
 - public health, 221
 - right to grant compulsory licences, 224
 - right to protect public health, 223
 - subsequent agreement, 215–19
- Doha Ministerial Conference, 75, 289
- Doha Ministerial Declaration, 196, 202
- Doha-type Declaration on Intellectual Property Rights and Climate Change, 5, 7, 347
- Domestic implementation, 205
- Dominant position, 332, 339–40
- DSU, 160
 - Article 3.2, 160, 231
 - customary rules of interpretation of public international law*, 161
- Durban, 105
 - Durban Agreement, 105
- East Asian countries, 252
- EC
 - EC – Approval and Marketing of Biotech Products* (2006), 184, 294
 - EC – Bananas III* (Article 21.5 – US)/ (Article 21.5 – Ecuador II) (2008), 178
 - EC – Bananas III (Ecuador)* (Article 22.6 – EC), 85
 - EC – Chicken Cuts* (2005), 173–75, 179–80
 - EC – Computer Equipment* (1998), 169, 190
 - EC – Hormones* (1998), 266
 - EC and certain member States – Large Civil Aircraft* (2011), 185
 - EC Treaty
 - Article 82, 316
- Economic development, social development and environmental protection, 199
- Economic, social and environmental concerns, 202–3
- Ecuador, 235, 363
- EGTT, 92, 94
- Emerging countries, 33–34, 36–38, 99, 138, 143, 153, 156, 244, 347
- Enabling environment, 272, 358
- Enforcement of IPRs, 118–19
 - civil sanctions, 114
 - criminal penalties, 114
 - effective domestic enforcement, 118
 - effective remedies, 119
 - Part III of TRIPS, 119
- Environmental protection, 214, 250, 255, 308, 350
- Equity, 80, 128, 260, 316
- Erga omnes*, 116

- Essential facility doctrine, 339–40, 343
 - “new product” criterion, 341
 - exceptional circumstances test, 340
 - IMS* (2004), 341
 - indispensable, 340
 - Magill* (1995), 340
 - Microsoft* (2007), 341
 - secondary market, 340
 - US jurisprudence, 340
- Essential patents, 367
- EST transfer commitments, 79, 87, 230, 308
- ESTs
 - bio-fuels, 112, 137, 240
 - carbon capture and storage, 125
 - carbon storage, 241
 - clean energy technologies, 25, 126, 138
 - defining, 13–15
 - Agenda 21 definition*, 14
 - Examples*, 15
 - UNFCCC*, 15
 - differentiated IP regimes, 245
 - global public goods, 25–26
 - international externality effects*, 25
 - key features, 14
 - low carbon technologies, 137
 - protected by different types of IPRs, 149
 - PV solar, 125
 - renewable energy technologies, 113, 125–26, 241
 - Solar PV, 137
 - special treatment for ESTs, 121
 - system technologies, 307
 - wind energy technologies, 127, 137, 147, 149
- EU, 244
 - EU position for the Copenhagen Climate Conference, 103
 - European Commission Decision, 332
 - European Patent Convention (2013)
 - Article 56*, 248
 - European Court of Human Rights, 182
- Ever-greening, 242
- Exceptions and limitations to patents, 227
- Exceptions to patent rights
 - Article 30 of the TRIPS Agreement, 259
 - Article 9.2 of the Berne Convention, 260
 - authorisation, 259
 - Canada – Pharmaceutical Patents* (2000), 259, 262, 271
 - limited, 260
 - non-commercial experimental use, 261
 - prior use, 271
 - prior use rights, 261
 - private use, 271
 - private, non-commercial purposes, 271
 - research or an experimental use exception, 271
 - research or experimental purposes, 271
 - Canada – Pharmaceutical Patent* (2000), 271
 - safe harbour, 259
 - scientific use, 271
 - scope, 260
 - statutory exceptions, 261
 - taking account of the legitimate interests of third parties, 260
 - technology-neutral, 244
 - three-step test, 260
 - unreasonably conflict with the normal exploitation, 260
 - unreasonably prejudice the legitimate interests of the patent owner, 260
 - use aboard vessels temporarily, 261
- Exclusive effects, 122, 140, 156, 309, 350, 353
- Exclusive rights, 256, 279, 311, 337
 - scope, 269
- Exhaustible natural resources, 201
- Exhaustion of patent rights, 273–76
 - Article 6 of TRIPS, 275
 - Doha Declaration, 276
 - Footnote 6 of TRIPS, 275
 - international exhaustion of patent rights, 275
 - national exhaustion of patent rights, 275
 - regional exhaustion of rights, 274
- Experimental use exceptions, 273
- Expressio unius est exclusio alterius*, 241
- Externalities, 26–28
 - environmental externalities of ESTs, 127
 - negative environmental externalities, 125
- Failure to work, 51, 279, 287–88, 309, 354
- FDI, 18–20, 48, 71, 122, 133–36
- Financial mechanism, 84, 106
- First sale. *See* exhaustion of patent rights
- Follow-on innovation, 140–41, 153–55, 249–50, 308, 339, 349, 352, 366
- Fossil fuels, 15, 25, 126
- FRAND, 366, 368
- Free-rider, 31, 132
- Free-riding, 25, 45, 70, 77, 123, 155, 341, 349
- FTAs, 4, 98

- G77, 54, 58, 99
 GATS, 255
 Article XIV, 209
 GATT, 55, 59, 61, 193–94, 204, 231, 234, 240, 255, 275
 Article XX, 208, 210
 Brazil – Retreaded Tyres (2007), 255
 Article XX(b), 208
 necessary, 208
 otherwise inconsistent, 208
 Article XX(d), 61, 69
 Article XX(g), 201
 process and structure of, 69
 GATT 1947, 189, 195, 204
 GATT CONTRACTING PARTIES, 180
 GATT negotiations, 62
 GEF, 84
 General Council, 217, 224, 275
 General Electric, 101, 146
 Generalised System of Preferences (GSP), 63
 Generic medicines, 146
 Germany, 35–36, 44, 252
 German patent law, 290
 GHG-reducing technologies, 143
 GHG emissions, 2, 79, 86, 94, 290, 368
 Goldwind Global, 150
 Good faith, 171, 288
 Green Climate Fund, 367
 Grey-market imports. *See* parallel imports
 Guide to the Application of the Paris
 Convention for the Protection of
 Industrial Property, 284
 Guidelines for licensing IP-protected ESTs,
 368

 High licensing fees, 145, 148–50, 153–54, 325
 High royalties, 47, 154, 321
 High standard of patentability, 251
 High technology products, 134
 Human Genome Project, 141
 Humanitarian or preferential licensing, 106,
 367

 ILC, 162–64, 166, 170–71, 174, 177–79, 185, 187,
 218
 Imitation, 61, 132, 142, 243
 creative imitation, 23
 duplicative imitation, 23
 imitation based catch-up and development
 approach, 23
 Korea, Japan, Singapore and the US, 23

 imitation-based technological development
 path, 142
 informal channels of technology transfer,
 22
 the legality of, 22
In dubio mitius, 294
 India, 37, 97, 137, 149, 152, 275
 India – Patent Protection (1997), 161
 India – Patents (US) (1997), 169
 Indigenous innovation, 143
 Industry characteristics, 243
 Information asymmetries, 26, 28, 368
 Innovation and transfer of technologies
 a central theme of, 2
 global response to climate change, 1
 in the negotiations, 2
 part of the solution to climate change,
 11–13
 Provisions for, 1
 to limit developing countries' greenhouse
 gas (GHG) emissions, 1
 Innovation of ESTs
 high concentration, 38–39
 highly concentrated, 3, 32
 Chatham House study, 35
 Dechezlepretre et al. (2011), 33
 UNEP, EPO and ICTSD (2010), 36
 Insufficient manufacturing capacities, 296,
 306, 310, 356
 Integral part, 116, 161, 168, 176, 198, 216
 Intellectual property rights (IPRs)
 a fairly high protection of, 2
 exclusive rights, 29
 exclusivity, 148
 expansion of, 32
 ius prohibendi, 139
 justification, 29–32
 incentives to create, 32
 rights-based property, 29
 utilitarian, 29
 legitimate barrier to free trade, 62
 policy interventions, 28
 private rights, 119
 strengthening of, 43
 revenue transfer, 45
 to incentivize innovation, 2
 International Court of Justice
 Aerial Incident Case (1959), 165
 Gabčíkovo-Nagymaros Project case, 199
 Land, Island and Maritime Frontier Dispute
 (1992), 171

- Peace Treaties with Bulgaria, Hungary and Romania* (1956), 167
- South West Africa Cases* (1962), 172
- International Exhibition of Inventions in Vienna, 50
- International IP conventions, 68, 77, 118
- International transfer of ESTs
- empirical study, 38
 - literature review, 33–38
 - rarely transferred to developing countries, 33
- Invent around, 122, 131, 140, 272, 309, 353
- Inventing around, 272
- Invention, 246
- dictionary meaning, 246
 - direct technical result, 247
 - genuine inventions, 250
 - minor/incremental innovations, 250
 - related to public health and nutrition, 219
- Inventions pertaining to ESTs, 240, 246, 250, 253
- IPC, 35, 37
- IPCC, 1, 127
- 4th Assessment Report, 92
 - Report (2014), 143
 - Special Report on Technology Transfer, 11
- IPR-related anti-competitive and abusive practices, 313
- James Watt, 141
- Japan, 20, 35–36, 39, 72, 141, 244
- Japan – Alcoholic Beverages* (1996), 162, 173, 180, 187
- Johannesburg Declaration, 198
- Judicial restraint, 170
- Know-how, 2, 11, 14, 20, 26, 83, 84, 90, 118, 131, 306, 310, 361
- Korea, 20, 35–36, 72, 142, 152
- Korea – Dairy Safeguards* (1999), 168, 174
 - Korea – Various Measures on Beef* (2001), 210
- Kyoto Protocol, 87–91, 96, 127, 145
- Article 10, 80
 - Article 10(c), 88
 - Article 11.2, 88
 - Article 12, 90
 - Article 3.14, 87
 - enabling environment, 88
 - first commitment period, 87
 - legally binding emission reduction obligation, 87
 - the role of the private sector, 87
- LDCs, 2, 38, 45, 68, 74, 76, 99, 155, 234, 367, 368
- Legitimate interest, 131, 272
- Legitimate interests, 213, 257, 269, 295
- Canada – Pharmaceutical Patents* (2000), 268
 - of third parties, 270, 273
- Level of compensation, 294–95, 338, 343
- Level of the technological development, 121
- License, 35–36, 89, 152, 296, 343, 368
- Licensing, 135
- Licensing agreement, 37, 47, 150, 154, 329, 335
- Licensing practices, 60, 138, 143, 320, 326, 328, 330, 335, 365
- Lima Draft, 105
- Limitations or exceptions, 257, 309, 353
- the art of the policy balance, 257
- Limited exception, 266–67
- Canada – Pharmaceutical Patents* (2000), 262
 - EC – Hormones* (1998), 266
- Local working requirements, 239, 282–89
- Brazil
 - local manufacture requirement*, 286 - Canada – Pharmaceutical Patents* (2000), 287
 - definition, 284
 - importation, 285
 - legality of, 286
 - legality of production-based, 286
 - local production, 285
- Low standards of patentability, 250–51
- low-quality EST patents, 251
- Low-quality patents, 147–48, 252, 308, 352
- Mandatory minimum patent standards, 234
- Manifestly absurd or unreasonable, 162, 165, 187
- Market dominance, 146
- Market exclusivity, 113, 267
- Market failure, 26, 127
- externalities, 27
 - information asymmetry, 27
 - market power, 28
- Market power, 24, 28, 74, 133, 139, 148, 154
- Marrakesh Agreement, 161, 168, 192, 194–96, 201, 203, 207, 216, 231, 350
- Article IX:2, 216
- authoritative interpretation*, 217
 - implied recommendation*, 217
 - recommendation by the Council*, 217

- Marrakesh Agreement (cont.)
 Article XVI:3, 192
 object and purpose, 193
 Preamble, 193–94, 226, 270
US – Shrimp (1998), 193
- Max Planck Declaration on Patents Protection, 192, 235–36
- Max Planck Institute for Innovation and Competition, 192
- MEAs, 60, 78–79, 83, 108, 186
- Measures to protect public health, 223
- MFN, 65, 67, 112, 275–76
- Minimum IPR protection standards, 344, 350, 355
- Minimum IPR standards, 98, 110
 ‘Berne-plus’ or ‘Paris-plus’, 67
 Article 1.1 of TRIPS, 66
 commitments, 65–69
 concerns, 120
 controversy over the effect of, 119–21
 effects on technology transfer, 120
 enforcement of IPRs, 118–19
 implications, 69–74
 mandatory treaty obligation, 72
 patent protection, 111–14
 protection of trade secrets, 114–18
 regulatory “floor”, 72
 reinforced the power of private parties, 120
 the effect on innovation and technology transfer, 121
- Minimum standards for IP protection and enforcement. *See* Minimum IPR standards
- Ministerial Conference, 215–16, 218, 228
- Ministerial Declaration, 179, 215, 226
 Doha Ministerial Declaration, 212
 Ministerial Declaration for climate change, 232, 351
 Punta del Este Declaration, 62, 204
- MNCs, 48, 52, 61, 134, 144, 153–54, 311, 325, 349, 368
- Monopoly, 63, 117, 128, 139, 146, 148, 154, 250, 283, 339
- Montreal Protocol, 79, 97, 149, 151
- Mutually reinforcing, 163, 201
- Mutually satisfactory solution, 239
- Mutually supportive, 202
- Napoleonic Code, 30
- National development strategies, 233
- National emergency, 224, 281, 283, 292, 302, 353, 360
- National emergency or other circumstances of extreme urgency, 302
- National patent laws, 51, 247, 271, 279, 283–84
- National security, 282
- National treatment, 65, 67, 112, 233, 275–76
- Necessity requirement
 Article XX of the GATT, 209
Brazil – Retreaded Tyres (2007), 210
Korea – Various Measures on Beef (2001), 210
 weighing and balancing, 210
- New Delhi Declaration of Principles of International Law Relating to Sustainable Development, 198
- NGOs, 16, 239
- No patents proposal, 100
- Non-discrimination clause, 112, 237–39
 Article 27.1, 237
 availability of patents, 238
 bona fide exceptions, 245
Canada – Pharmaceutical Patents (2000), 243, 245
 certain product areas, 245
 differential treatment, 240
 differentiate, 243
 discrimination, 242
 enjoyment of patent rights, 238
 ESTs, 240
differential treatment, 241
field of technology, 241
function of the technology, 241
 importation, 239
 imported and locally produced products, 239
 local working requirements, 239
 non-discrimination as to the field of technology, 239–46
 patent-specific, 237
 place of invention, 238
 scope of application, 238
 structural effect, 244
 technological neutrality principle, 239
 unjustified differential treatment, 243
- Non-discriminatory, 50, 65, 69, 195, 202, 275, 287, 367
- Non-patentability, 252
 contributes to protecting *ordre public* and morality, 253
 morality, 253

- necessity test, 255
- ordre public*, 253
- prohibit commercial exploitation, 254
- Non-trade concerns, 232, 350
- Non-trade-related concerns, 195
- Non-WTO norms, 236, 308, 352
- Non-WTO treaties, 185
- Normal exploitation, 113, 259–61, 263, 267–68, 273
 - Canada – *Pharmaceutical Patents* (2000), 113
 - not unreasonably, 268
- North-South, 3, 55, 64
- Nuclear energy, 126
- Object and purpose, 66, 85, 161, 163, 172–73, 204
 - Article 31(1) of the VCLT, 172
 - EC – *Chicken Cuts* (2005), 173
 - from the text of the treaty, 173
 - Japan – *Alcoholic Beverages* (1996)
 - not as an independent basis for interpretation, 173
 - of particular treaty's provisions, 173
 - of the entire treaty, 173
 - preamble, 173
- Object and purpose of the treaty, 172–73, 192, 261
- Objective of sustainable development, 193–97, 201, 203
 - 2001 Doha Ministerial Declaration, 196
 - US – *Shrimp* (1998), 195
- OECD countries, 33–35, 39, 42–43
- One-size-fits-all, 156, 243
- OPEC, 106
- Open-textured, 231–32, 234, 350–51
- Ordinary meaning, 85, 161, 170–72, 174, 203, 231, 261, 288, 319, 323, 350
 - Article 31(1) of the VCLT, 170
 - dictionary definitions, 171
 - not *dispositive*, 171
 - essence of the textual approach, 170
 - fully qualified, 172
 - in its context and in light of the object and purpose of the treaty, 171
 - terms of the treaty, 170
- Ordre public*, 253–55, 308, 353
 - environmental protection, 253
 - to avoid serious prejudice to the environment, 254
- Ozone-friendly technologies, 97, 148, 151–52
- Pacta sunt servanda*, 164
- Paragraph 6 system, 298, 299, 304
 - Decision of 30 August 2003, 298
 - insufficient manufacturing capacity, 298
- Rwanda, 299
- waivers, 298
 - adequate remuneration, 299
- Parallel imports, 226, 232, 274–77, 309, 351, 353
 - international exhaustion of rights, 276
 - practicability and feasibility, 276–77
- Paris Agreement, 2, 94–96, 106
 - Article 10.4, 95
- Paris Climate Change Conference, 94
- Paris Convention, 50–51, 66, 111, 120, 190, 236–37, 279, 284
 - Article 5(A)(2)
 - failure to work, 284, 287
 - Article 5A, 54, 297
 - Article 5A(2), 279, 297
 - demand for the revision of, 51
 - the Stockholm Act (1967) of, 55
- Patent abuse, 47, 52, 219, 298
- Patent applications, 36, 50, 111, 126, 145, 308, 352
 - EST, 39
 - fast track mechanisms, 246
- Patent blockage, 145, 147, 154
 - effects of, 147
 - patent clusters, 145
 - patent litigation, 147–48
 - patent thickets, 145
 - the tragedy of anti-commons, 147
- Patent boom, 126, 145
- Patent claim, 131, 272, 309, 353
- Patent disclosure, 36, 130–32, 155, 272, 349
- Patent disclosure requirement
 - “social contract” theory, 128
 - Article 29.1 of the TRIPS Agreement, 128
 - best mode requirement, 129
 - effectiveness, 130
 - enabling requirement, 131
 - sufficiency of disclosure, 129
- Patent document, 33, 129–30, 145
- Patent information, 129, 241
 - databases, 130
 - role of, 132
 - use for experimental purposes, 131
- Patent infringement, 147

- Patent misuse
 - mandatory package licensing, 318
 - price discrimination, 318
 - refusal to license, 318
 - resale price maintenance, 318
 - tying, 318
- Patent office, 148, 252, 308, 352
- Patent pools, 105–6
- Patent rights
 - Article 28.1 of TRIPS, 113
 - limits, 256–58
 - qualify and limit, 235
 - right of importation, 113
- Patent system, 53–54, 118, 124, 128, 132, 234, 236, 243, 245, 257, 271, 285, 308, 352
- Patent term, 73, 113, 131, 269
- Patent thickets, 115, 146
- Patentability, 4, 111, 129, 148, 202, 235, 237–38, 240–41, 246–47, 249–50, 253–55, 308, 352
 - general obligation of, 112
- Patentability requirements, 234, 236, 246–49, 252, 352
 - all fields of technologies, 237
 - an inventive step, 248
 - Article 27 of the TRIPS Agreement, 236
 - capable of industrial application, 247
 - first sentence of Article 27.1, 246
 - non-obvious, 248
 - a person skilled in the art*, 248
 - non-obviousness, 148
 - novelty requirement, 247
 - useful, 249
- Patentable subject matter, 7, 73–74, 159, 235–36
 - blanket exclusions, 112
- Patented process, 113, 278, 284, 286
- Patent-related flexibilities, 6, 231, 235–36, 307–8, 310, 350, 352, 359
- Patent-sensitive industries, 125
- PATSTAT, 33, 138
- PCT, 38, 111, 146
- Per se*, 170, 319, 334
- Permanent Court of International Justice, 166
 - Competence of the ILO in regard to International Regulation of the Conditions of the Labour of Persons Employed in Agriculture*, 166
- Permissible exclusion
 - Article 27.2 of TRIPS, 253–56
- Permissive, 257
- Pharmaceuticals, 66, 112, 124–25, 134, 150, 219, 245, 298, 307
- Policy space, 73, 195, 210, 214, 233, 303, 313, 323, 350
- Positive integration, 69
- Post-Kyoto climate negotiations, 304
- Post-Kyoto climate regime, 91
- Preamble, 193, 209, 328
- Preparatory work, 174, 188–90
 - US – *Carbon Steel* (2002), 189
- Principle of effectiveness, 166–68, 197, 263–64
- Principle of equity, 80, 128
- Principle of good faith, 164–70, 317
 - Article 31(1) of the VCLT, 162
 - reasonableness, 165
 - the principle of effectiveness, 166–68
 - as a whole*, 168
 - Canada – *Pharmaceutical Patents* (2000), 167
 - harmoniously*, 168
 - Korea – *Dairy Safeguards* (1999), 168
 - US – *Gasoline* (1996), 167
 - the principle of the protection of legitimate expectations, 166, 168–70
 - common intentions of the parties*, 169
 - EC – *Computer Equipment* (1998), 169
 - India – *Patents* (US) (1997), 169
 - US – *Underwear* (1997), 169
 - ut res magis valeat quam pereat*, 166
- Principle of integration, 199, 202
 - Gabčíkovo-Nagymaros Project* (1997), 200
 - Iron Rhine* case (2005), 201
 - Johannesburg Declaration on Sustainable Development, 199
 - New Delhi Declaration, 199
 - Rio Declaration, 198
 - Rio+20 outcome document, 199
 - US – *Shrimp* (1998), 201
- Principle of reconciliation, 200
- Principle of sustainable development, 198, 200–1, 203
- Principle of systemic integration, 185
 - Bankovic v. Belgium and others* (2001), 182
 - coherence and meaningfulness, 182
 - US – *Gasoline* (1996), 182
 - US – *Shrimp* (1998), 182
- Prior art, 247
- Prior negotiations, 303, 343
- Private rights, 64, 156, 205
- Private sector, 88, 96, 103, 125, 144, 154, 160, 346, 365, 367

- Pro-competition provisions, 74, 231
- Protect public health, 207, 211, 216, 221, 223, 226
- Protection of the environment, 195, 200, 202
- Public domain, 31, 72, 88, 100, 117, 123, 128, 249–51, 352
- Public good, 25, 29, 208
- appropriability problem, 26
- free ride, 25
- non-excludable, 25
- non-rival, 25
- Public goods, 25–27, 31, 296
- Public health, 71, 74, 208, 211, 221, 223, 225, 228, 232, 261, 279, 289, 297–98, 302, 306, 351
- Public interest, 159–60, 195, 207, 210, 214, 226, 232, 234, 257–58, 264, 268, 278, 297, 301, 312, 321, 323, 325, 344, 346, 350, 352
- concept, 208–9
- Public interests, 121, 282, 293, 341
- Public order. *See* *ordre public*
- Public policies, 211, 269
- Public policy goals
- mitigating climate change, 122
- Public policy objectives, 194, 209, 213, 226, 232–34, 298, 351
- Quality of patent. *See* patent quality
- R&D investment, 25, 31, 40–41, 123, 125
- Reasonable, 319
- reasonable commercial terms, 151, 153, 292
- reasonable terms, 53, 325
- Reasonableness, 368
- Reconcile and integrate, 203
- Reconciling, 5, 160, 201, 203, 346
- Refusal to deal, 140, 152
- Refusal to license, 141, 144–45, 150–53, 321, 339, 341
- Refuse to deal, 70, 154, 302, 309, 354
- Refuse to license, 150, 153, 311, 339, 341–42, 349, 368
- Regulation governing international technology transfer
- market-based development model, 47
- NIEO Model
- revision of the Paris Convention*, 48
- TOT Code*, 48
- Regulatory discretion, 276, 287, 313
- Regulatory flexibility, 237
- Regulatory review exception. *See* Bolar exemption
- Regulatory sovereignty, 225, 322, 344, 359
- Relevant market, 330, 333–34, 337, 339–40, 368
- Relevant rules of international law, 5, 185, 214–15, 232, 351
- applicable in the relations between the parties, 229
- Article 31(3)(c) of the VCLT, 181–86
- Article 38(1) of the Statute of the International Court of Justice, 183
- Article 4.5 of the UNFCCC, 229
- EC – Approval and Marketing of Biotech Products* (2006), 184
- parties
- a subset of all the parties*, 186
- EC and certain member States – Large Civil Aircraft* (2011), 185
- the parties to the dispute*, 185
- relevant, 186
- Report of the Energy and Resources Institute, 149
- Restrictive practices, 47, 52, 57–58, 319, 334
- Reverse engineering, 18, 23, 72, 117, 125, 142–43
- legality of, 117
- Right to grant compulsory licences, 224, 300, 360
- Right to health, 226
- Right to importation
- Article 28, 276
- Right to protect the environment, 360
- Right to protect the public interest, 253
- Right to refusal to deal, 340
- Right to refuse to license, 339
- Rio Declaration, 195, 198
- Rio Earth Summit, 14, 49, 79, 195
- Rio+20 Outcome Document, 198, 302
- Role of IPRs
- a double-edged sword, 155, 349
- a prerequisite to transfer ESTs, 132–39
- an enabling factor for innovation of ESTs, 122–32
- an important factor influencing EST transfer, 137–39
- context-specific, 155, 349
- essential incentives for innovation and transfer of ESTs, 122
- exclusive effects of IPRs, 140–43
- impediment to access to medicine, 222
- incentive effects on innovation of ESTs, 123–27
- incentive to disclose, 29, 123, 128
- incentive to innovate, 122
- contingent on the characteristics of the industry*, 124

- Role of IPRs (cont.)
 incentivising effects, 241
 industry- and country- specific, 123
 may hinder EST transfer, 139–45
 positive role, 121–32
 potential anti-competitive practices, 143–55
 role of patent-induced information
 disclosure in innovation of ESTs,
 128–32
 Russia, 33, 37
 Rwanda, 299
- Safeguards, 63, 73, 119, 159, 219, 248, 291
 SBI, 93
 SBSTA, 92
 SCP/15/3, 227
 Second uses of patents, 252
 Semiconductor technology, 280
 Single Undertaking, 167–68, 174, 387
 Small island developing countries (SIDCs),
 367
 SMEs, 252
 Social and economic welfare, 159, 206–7, 210,
 323
 Special and differential treatment principles,
 69
 Special needs of developing countries, 56
 Spill-over, 17
 SPS Agreement, 294
 Standard essential patents, 147, 332
 State intervention, 304
 State-of-the-art. *See* prior art
 Statute of the International Court of Justice
 Article 38(1)(d), 191
 Stockpiling exception, 262
 Subsequent agreement, 176–78, 214–15, 218,
 226, 351
 “subsequent” to, 178
 agreement, 177
 single common act, 178
 US – *Clove Cigarettes* (2012), 177
 application
 EC – *Bananas III* (Article 21.5 – US) /
 (Article 21.5 – Ecuador II) (2008), 178
 Article 31(3)(a) of the VCLT, 177
 authentic element of interpretation, 178
 Doha Declaration, 215–19
 relate either to the interpretation or
 application of the treaty, 178
 Subsequent practice, 168–228, 232, 351
 accept tacitly, 180
 Article 31(3)(b) of the VCLT, 179–81
 authentic element of interpretation, 179
- Canada – *Pharmaceutical Patents* (2000),
 227
 common understanding of all the parties,
 181
 concordant, common and consistent, 180
 EC – *Chicken Cuts* (2005), 179–80
 imply agreement on the interpretation, 180
 Japan – *Alcoholic Beverages* (1996), 180
 lack of reaction, 181
 US – *Gambling* (2005), 180
 US – Section 110(5) *Copyright Act* (2000),
 227
 Sufficient manufacturing capacities, 299, 307
 Supplementary means of interpretation, 162,
 187, 191
 ambiguous or obscure, 187
 Article 32 of the VCLT, 186
 circumstances of the conclusion, 189–90
 confirming, 170
 EC – *Chicken Cuts* (2005), 174
 including, 191
 The Canadian Cattlemen for Fair Trade
 v. *United States of America*, 191
 Japan – *Alcoholic Beverages* (1996), 187
 judicial decisions, 191
 manifestly absurd or unreasonable, 187
 may, 188
 means to aid an interpretation, 187
 preparatory work, 188–89
 subsidiary, 187
 teachings of publicists, 191
 Sustainable development, 12, 90, 193–97, 202,
 214, 270, 351, 363
 definition, 198
 international customary law, 202
 legal status, 197
 Gabčíkovo-Nagymaros Project, 199
 give effect to, 197
 overarching objective of the WTO, 196
 US – *Shrimp* (1998), 197
 mutually reinforcing pillars, 199
 objective of the WTO, 193
 Preamble to the Marrakesh Agreement, 193
 principle of integration and reconciliation,
 198
 Sustainable development objective, 231, 235,
 273, 288, 308, 324, 344, 346, 350
 Switzerland, 51, 72, 142
- Take account of
 EC – *Approval and Marketing of Biotech*
 Products (2006), 294
 US – *Clove Cigarettes* (2011), 294

- TBT, 294
 - Article 12.3, 294
 - Technical effect, 267
 - Technological capabilities, 21, 79, 235, 251, 304
 - Technological capacities, 20, 22, 37, 56, 70, 138–39
 - Technology
 - dictionary meaning, 13
 - what the term “technology” means, 13
 - Technology Executive Committee, 94–95
 - Technology Mechanism, 94–95
 - Technology transfer
 - and technology dissemination (diffusion), 17
 - Channels, 18–25
 - FDI, 19
 - Imitation, 22
 - Licensing, 19–20
 - Reverse engineering, 23–25
 - Trade, 21–22
 - Definition, 16–18
 - Foray (2009), 17
 - IPCC, 16
 - World Intellectual Property Organisation (WIPO), 16
 - direction of international technology transfer, 41–42
 - market-based channels, 365
 - mechanisms, 92–94
 - not taken place at a scale large enough, 3
 - part of the bargain, 74
 - provisions
 - very little actual and effective implementation*, 2
 - provisions that govern or facilitate, 74–78
 - UNCTAD Draft International Code of Conduct on the Transfer of Technology, 13
 - Technology transfer and IPRs
 - Bali Road Map, 98
 - controversy, 96
 - international climate change regime, 96–106
 - Telecommunications industry, 146
 - Test data, 65, 114
 - Three-step test
 - Canada – Pharmaceutical Patents* (2000), 262
 - comprehensive overall assessment, 264
 - cumulative basis, 262
 - limited exception, 262
 - unreasonably conflict with a normal exploitation of the patent, 267
 - unreasonably prejudice the legitimate interests, 268
 - US – *Section 110 (5) Copyright Act* (2000), 263
 - Trade restrictive, 255
 - Trade secret law, 117
 - Trade secrets, 65, 114–18, 121, 130, 149
 - a manner contrary to honest commercial practices, 116
 - bad faith*, 116
 - Footnote 10 to Article 39.2 of TRIPS, 116
 - subjective standard of analysis*, 116
 - Article 1.2 of TRIPS, 115
 - Article 39.1 of TRIPS, 114
 - Article 39.2 of TRIPS, 116
 - duty to protect confidential information, 116
 - indefinitely, 117
 - information lawfully within their control, 115
 - non-disclosure nature, 118
 - reverse engineering, 117
 - role, 118
- Transfer of ESTs, 78
 - Bali Action Plan, 91–92
 - clauses, 83
 - commitments, 82–85
 - Article 4.5 of the UNFCCC, 83
 - Kyoto Protocol, 87
 - Transition period, 45, 224
 - Transitional periods, 68, 78, 234
 - staggered implementing periods, 220
 - Travaux préparatoires*, 187, 240
 - Treaty interpretation, 161, 323, 356
 - a holistic exercise, 163
 - authoritative interpretation, 217
 - contextual interpretation, 174
 - evolving interpretations, 215
 - good faith interpretation, 289, 328
 - inherent limitations, 170
 - not a rigid sequence of discrete steps, 163
 - primary, obligatory sources of, 214
 - textual approach, 170
 - textual, systemic and teleological methodologies, 164
 - US – *Continued Zeroing* (2009)
 - a holistic exercise, 163
 - TRIPS
 - adoption of, 45
 - Article 1.1, 65
 - Article 1.1, first sentence, 328
 - Article 13, 260
 - Article 2.1, 297
 - Article 27
 - boundaries to patentability*, 236

TRIPS (cont.)

- Article 27.1, 112, 286, 352, 354
 - field of technology*, 240
 - first sentence*, 240
 - non-discrimination principle*, 308
 - obligation of non-discrimination*, 237
 - patentability requirements*, 246
 - purposive interpretation*, 288
 - travaux préparatoires*, 112
- Article 27.2, 308, 353
 - Non-patentability*, 253
- Article 28, 267
 - exclusive rights*, 259
- Article 28.1, 113
- Article 28.2, 113
- Article 29.1, 128
- Article 30, 131, 309, 353
 - Canada – Pharmaceutical Patents (2000)*, 261
 - Exceptions to Rights Conferred*, 259–73
 - three-step test*, 260
- Article 31
 - government use*, 281
 - Other Use Without Authorization of the Right Holder*, 281
- Article 31(a)
 - on its individual merits*, 291
- Article 31(b)
 - national emergencies or other circumstances of extreme urgency*, 290
 - prior negotiation requirement*, 292
 - public non-commercial use*, 290, 292
 - reasonableness*, 292
- Article 31(c)
 - scope and duration*, 295
- Article 31(f)
 - predominantly for the supply of the domestic market*, 296, 338, 343
- Article 31(h)
 - adequate remuneration*, 294, 338
 - taken into account*, 294
- Article 31(i) and (j)
 - independent review*, 293
- Article 31(k), 312, 343, 344
 - anti-competitive practice*, 290
 - refuse termination of authorisation*, 338
- Article 39, 115
 - an unfair competition law provision*, 116
- Article 4, 68
- Article 40, 312, 321, 335
 - abuse*, 213

- Article 40.1, 326, 329
 - adverse effects on trade and technology transfer*, 327
 - affirmative obligation*, 328
 - non-binding “chapeau”*, 327
 - obligation to regulate*, 327
 - restrain competition*, 327
- Article 40.2, 326, 329–30, 332, 334
 - an adverse effect on competition*, 331
 - coercive package licensing*, 335
 - conditions preventing challenges to validity*, 335
 - effect on competition*, 333
 - exclusive grantback conditions*, 335
 - first sentence*, 330
 - include*, 335
 - IPR-specific anti-competitive practices*, 333
 - particular cases*, 333
 - rule of reason*, 333
 - second sentence*, 334
- Article 40.3 and 40.4, 326
- Article 41.1, 119
- Article 48.1, 318
- Article 6, 353
- Article 61, 114
- Article 64, 67
- Article 66.2, 2, 74–77, 156
 - implementation of*, 77
 - negotiating history*, 75
 - shall*, 75
 - the effect of*, 76
- Article 67, 345, 357
 - technical and financial cooperation*, 336
- Article 7, 2, 74, 205–7, 255, 308, 328
 - “should” provision*, 206
 - a balance of rights and obligations*, 206
 - Canada – Pharmaceutical Patents (2000)*, 207
 - Doha Declaration*, 206
 - in mutually beneficial ways*, 206
 - operational*, 120
 - promote innovation and transfer and the dissemination of technology*, 206
 - the overall goal of promoting social and economic welfare*, 207
- Article 8, 290
 - public interest principle*, 308
- Article 8.1, 207–11, 321
 - a proper relationship of means and ends*, 210
 - consistency requirement*, 210–11

- consistent with*, 208
- measures to promote public interest*, 208
- necessary*, 208–10
- proportionality of measures*, 210
- protection of public health and nutrition*, 208
- public interest in ESTs sectors*, 211
- public interest principle*, 208
- socio-economic and technology development*, 208
- weighing and balancing*, 210
- Article 8.2, 312, 327, 343, 354
- abuse of IP rights*, 316
- adversely affect the international transfer of technology*, 333
- appropriate measures*, 315, 325
- Basic Principle*, 314–22
- consistency requirement*, 315, 322–24
- interpretative function*, 315
- overarching, constitutional principle*, 314
- policy statement*, 314
- practices which unreasonably restrain trade*, 320
- Articles 28 and 33, 256
- Articles 30 and 31, 281
- Articles 40.1 and 40.2, 335
- Articles 7 and 8, 235, 257, 266, 270, 273, 297, 324, 329, 331, 344, 351
- balancing objective and purpose*, 205
- balancing objectives*, 213
- Canada – Pharmaceutical Patents (2000)*, 212
- Doha Ministerial Declaration*, 212
- interpretative role*, 213
- objective clues*, 213
- shall guide the interpretation*, 198
- Articles 8.2 and 40, 60, 312
- balanced nature*, 207
- balancing objective*, 232, 350
- centrepiece of the global system of rules*, 49
- costs and benefits*, 71
- emergence*, 60
- “A” texts*, 63
- “B” texts*, 64
- forum shifting*, 61
- Footnote 6, 275
- Footnote to Article 31
- other use*, 281
- general purpose*, 119
- history of negotiations of the treaties incorporated into the TRIPS*, 190
- Canada – Pharmaceutical Patents (2000)*, 190
- inconsistent with*, 328
- incorporating the Paris Convention*, 112
- mandating effective domestic IP rights enforcement*, 119
- minimum standards agreement*, 65
- most comprehensive multilateral agreement on IP*, 60
- negotiating history*, 190, 286, 324
- object and purpose*, 203–5, 214, 268, 343
- objective and purpose*, 346
- Paris-plus treaty*, 113
- Part II of TRIPS*, 110, 326
- Preamble*, 204, 324, 344
- reduce distortions and impediments to international trade*, 320
- Section 8
- Control of Anti-competitive Practices in Contractual Licences*, 326
- spirit and purpose*, 224
- technology transfer-oriented provisions*, 74–78
- third pillar of the WTO Agreement (Annex 1C)*, 64
- TRIPS amendment, 256, 299
- TRIPS Council, 73, 76, 212, 217, 220–21, 224, 235, 363, 365
- TRIPS flexibilities, 110, 159, 168, 220, 223, 225, 227, 235, 298, 307, 350–51, 356, 359–60
- availability, sufficiency and effectiveness*, 234
- limits to patents*, 159
- pro-competitive measures*, 159
- TRIPS negotiations, 160, 280–81, 283–84, 334
- TRIPS negotiators, 77, 206, 268, 271, 275
- TRIPS-plus provisions, 4, 68, 72–74, 98
- UK Commission on Intellectual Property Rights, 142, 251
- UK Patents Act of 1883, 282
- UNCED, 14, 49, 96
- UNCLOS, 83–84
- Uncompensated spillovers*, 27
- UNCTAD, 57, 59
- UNCTAD Report (1974), 52

- UNCTAD TOT Code of Conduct
 “regulatory” approach to technology transfer, 56
 major characteristics, 55
 restrictive business practices, 57–59
 UNGA resolution 31/159 of December 1976, 57
- Undisclosed information, 65, 111, 114–16
- UNDP Human Development Report (2001), 298
- UNDP Human Development Report (2007), 306
- Unfair competition law, 131
 protection of undisclosed information, 116
- UNFCCC, 94, 96, 234, 358
 Article 11.1, 84
 Article 2, 11
 Article 3.1, 80–81
 Article 4.1, 82
 Article 4.1(c), 2, 15
 Article 4.3, 84
 Article 4.3 and 4.5, 106
 Article 4.5, 2, 83, 232, 236, 266, 273, 351
as appropriate, 85
EST transfer commitments, 352
take all practicable steps, 84, 155
 Article 4.7, 82, 85–87
 implementation, 85
 negotiations, 98, 305
- Unilateral abuses of IPRs, 140
- Unilateral trade sanctions, 63
- United States, 33, 35–36, 39, 43–44, 48, 53–55, 61, 70, 72, 135, 141, 154, 244
 American Clean Energy and Security Act, 102
 Atomic Energy Act, 282
 Foreign Relations Authorization Bill, 102
U.S. – Lead and Bismuth (1994), 165
 United States’ Constitution, 31
US – Anti-Dumping and Countervailing Duties (2011), 183
US – Carbon Steel (2002), 189
US – Chile FTA, 73
US – Clove Cigarettes (2011), 294
US – Clove Cigarettes (2012), 177
US – Continued Zeroing (2009), 163
US – Gambling (2005), 180
US – Gasoline (1996), 167, 182
US – Jordan FTA, 73
US – Morocco FTA, 73
US – Section 110 (5) Copyright Act (2000), 175, 263
US – Section 110(5) Copyright Act (2000), 227, 319
US – Section 301 (1999), 164
US – Shrimp (1998), 182, 193, 195, 197, 201, 226, 231, 316
US – Underwear (1997), 169
 US antitrust law, 334
 US Atomic Energy Act, 292
 US Clean Air Act, 282–83, 290, 292
 US Free Trade Agreement Implementation Bill 2004, 242
 US House of Representatives, 4, 102
 US Patent Act, 244
 US Patent and Trademark Office (USPTO), 251
 US patent law, 248–49
 US Supreme Court, 118, 317
Bonito Boats, Inc. v. Thunder Craft Boats, Inc., 128
US-Bahrain FTA, 73
US-Section 211 Appropriations Act (2002), 67
 Unreasonable, 154, 165, 207, 317, 319, 325, 344, 354
US – Section 110(5) Copyright Act (2000), 319
 Unreasonably restrains trade
 ‘balancing’ test, 319
 UNU-MERIT, 90
 Uruguay Round negotiations, 49, 64, 190, 280, 312
 Utility models, 51, 308, 352
- Vagueness, 234
- Voluntary licence, 290, 300, 338
- Voluntary licensing, 304, 362
- Waiver, 298, 306–7, 356
- Waxman-Markey Bill, 102
- Weighing and balancing, 210, 255, 334
- Weighing of the competing interest, 319
- Western European Countries, 72
- Wind turbine, 149–50, 307
- WIPO, 53, 55, 61, 63, 118, 129, 227, 248
 WIPO Diplomatic Conference on the Revision of the Paris Convention, 53
 WIPO Document SCP/15/3, 237
 WIPO Model Law for Developing Countries on Inventions, 247
 WIPO Patent Landscape Report on Ritonavir, 146
 WIPO treaties, 61, 118

World Bank, 20, 41, 44, 71, 84, 251	WTO Committee on Trade and Environment,
World trading system, 68–69, 160, 195	195, 234
World War II, 23, 51	WTO dispute settlement, 67, 275
WTO Agreement, 215, 231, 324	WTO Dispute Settlement Body, 203
WTO Agreements, 160, 165, 168, 174, 182–85,	WTO dispute settlement system, 160
193–94, 197–98, 201–2, 215–16, 231, 379	WTO panels, 172, 175, 187, 192, 245